Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) Director George M. Jenkins acquired 4,000 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were bought at an average cost of $12.93 per share, with a total value of $51,720.00. Following the completion of the acquisition, the director now owns 180,671 shares in the company, valued at approximately $2,336,076.03. This represents a 2.26 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Palvella Therapeutics Stock Up 1.4 %
NASDAQ:PVLA traded up $0.16 during trading hours on Thursday, reaching $11.95. The stock had a trading volume of 9,752 shares, compared to its average volume of 46,083. Palvella Therapeutics has a 52 week low of $6.20 and a 52 week high of $22.32.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald began coverage on shares of Palvella Therapeutics in a research note on Wednesday. They issued an “overweight” rating on the stock.
Featured Stories
- Five stocks we like better than Palvella Therapeutics
- Best Aerospace Stocks Investing
- Micron Stock Under $100: Seize the AI-Driven Upside
- How to Invest in Insurance Companies: A Guide
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- What Are Dividend Contenders? Investing in Dividend Contenders
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
